https://www.psychiatrist.com/esketamine-ciii-nasal-spray-treatment-resistant-depression/
The Journal of Clinical Psychiatry
Information from Industry June 30, 2020
SPRAVATO® (esketamine) CIII Nasal Spray: The First and Only N-Methyl D-Aspartate (NMDA) Receptor Antagonist Approved in Conjunction With an Oral Antidepressant for the Treatment of Adults With Treatment-Resistant Depression
Vol 87 • 2026 • Number 2
Read the Current Issue
Original Research
CBT following Esketamine for Major Depression and Suicidal Ideation for Relapse Prevention: The CBT-ENDURE Randomized Trial
Original Research
Neuropsychiatric Symptom Clusters and Brain Structure in Alzheimer’s Disease
Systematic Review
Thirty Years of the Diagnostic Criteria for Psychosomatic Research
Original Research
Efficacy of Olanzapine/Samidorphan on Negative Symptoms
Original Research
Comparing Risk Prediction for Suicide Attempts and Deaths After Emergency Department Visits
Clinical and Practical Psychopharmacology
Insomnia, Sleep, and the Use of Sedative-Hypnotic Drugs: Practical Notes
Related Articles
Information from Industry
Auvelity: A Rapid-Acting Antidepressant With Multimodal Activity
September 27, 2024
AUVELITY is an FDA-approved treatment for adults with MDD. Auvelity, is a rapid-acting antidepressant with a multimodal mechanism, targeting both glutamatergic and monoaminergic pathways. Learn more about how AUVELITY...
